Doxazosin Tablet
Product Images NDC 71610-789

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-789). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 4 mg (71610 0789 60)

Doxazosin USP 4 mg tablet label showing NDC 71610-0789-60. The label includes storage instructions to keep tablets between 20-25 degrees Celsius and to protect from light and moisture. It states this product is by Upsher-Smith Laboratories, Inc. in Maple Grove, MN, with repackaging by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. Additional details include barcode, batch, and expiration fields.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Doxazosin 01)

Chemical structure diagram of Doxazosin Mesylate, illustrating its molecular composition including aromatic rings, nitrogen-containing heterocycles, and methanesulfonic acid (mesylate) moiety.*

FDA Label Image

Table 3 (Doxazosin 02)

A data table and bar graph presenting results from three studies comparing placebo and doxazosin (at 4 mg and 8 mg) on symptom score and maximum flow rate. The table shows mean baseline and mean change values for symptom scores and maximum flow rates over study periods. The bar graph visualizes Study 2 maximum flow rate increases and symptom score decreases with doxazosin doses compared to placebo.*

FDA Label Image

Figure 1 (Doxazosin 03)

Figure 1 from Study 1 presenting two line graphs comparing Doxazosin and Placebo treatment effects over 14 weeks. The left graph shows mean change in total symptom score from baseline, with Doxazosin demonstrating a greater decrease than Placebo. The right graph depicts mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin showing a higher increase than Placebo. Sample sizes are N=50 for Doxazosin and N=47 for Placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.